The closest human evidence in its drug class is Athira Pharma's fosgonimeton (ATH-1017), a structurally distinct molecule in the same HGF/c-Met program whose Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint in September 2024 (GST 0.08, P=.70)
This results in an excess contribution of $3,850 2,888 = $962, which must be withdrawn from the HSA by the tax filing deadline of April 15, 2024, to avoid a 6% excise tax on the excess amount
This formula supports red blood cell formation through its combination of phosphorus, folic acid, and Vitamin B12
Ng and colleagues synthesized them, added a tyrosine at the start for better stability, and obtained AOD-9604 , Anti-Obesity Drug 9604, the code name of the development program